Suppr超能文献

肺栓塞的病理生理学与管理

Pathophysiology and Management of Pulmonary Embolism.

作者信息

Shah Ishan K, Merfeld John M, Chun Jimy, Tak Tahir

机构信息

Department of Family Medicine, Mayo Clinic Health System, La Crosse, Wisconsin.

Department of Nephrology, Mayo Clinic, La Crosse, Wisconsin.

出版信息

Int J Angiol. 2022 Sep 23;31(3):143-149. doi: 10.1055/s-0042-1756204. eCollection 2022 Sep.

Abstract

Pulmonary embolism (PE) is one of the most common etiologies of cardiovascular mortality. It could be linked to several risk factors including advanced age. The pathogenesis of PE is dictated by the Virchow's triad that includes venous stasis, endothelial injury, and a hypercoagulable state. The diagnosis of PE is difficult and is often missed due to the nonspecific symptomatology. Hypoxia is common in the setting of PE, and the degree of respiratory compromise is multifactorial and influenced by underlying cardiac function, clot location, and ability to compensate with respiratory mechanics. Right ventricular dysfunction/failure is the more profound cardiovascular impact of acute PE and occurs due to sudden increase in afterload. This is also the primary cause of death in PE. High clinical suspicion is required in those with risk factors and presenting signs or symptoms of venous thromboembolic disease, with validated clinical risk scores such as the Wells, Geneva, and pulmonary embolism rule out criteria in estimating the likelihood for PE. Advancement in capture time and wider availability of computed tomographic pulmonary angiography and D-dimer testing have further facilitated the rapid evaluation and diagnosis of suspected PE. Treatment is dependent on clinical presentation and initially involves providing adequate oxygenation and stabilizing hemodynamics. Anticoagulant therapy is indicated for the treatment of PE. Treatment is guided by presence or absence of shock and ranges from therapeutic anticoagulation to pharmacologic versus mechanical thrombectomy. The prognosis of patients can vary considerably depending on the cardiac and pulmonary status of patient and the size of the embolus.

摘要

肺栓塞(PE)是心血管疾病死亡的最常见病因之一。它可能与包括高龄在内的多种风险因素有关。PE的发病机制由Virchow三联征决定,包括静脉淤滞、内皮损伤和高凝状态。PE的诊断困难,由于症状不具特异性,常常被漏诊。低氧血症在PE患者中很常见,呼吸功能受损的程度是多因素的,受基础心脏功能、血栓位置以及呼吸力学代偿能力的影响。右心室功能障碍/衰竭是急性PE更严重的心血管影响,是由后负荷突然增加所致。这也是PE患者死亡的主要原因。对于有风险因素且出现静脉血栓栓塞性疾病体征或症状的患者,需要高度临床怀疑,并使用经过验证的临床风险评分,如Wells评分、Geneva评分和肺栓塞排除标准来评估PE的可能性。计算机断层扫描肺动脉造影和D-二聚体检测在采集时间方面的进展以及更广泛的可及性,进一步促进了对疑似PE的快速评估和诊断。治疗取决于临床表现,最初包括提供充足的氧合和稳定血流动力学。抗凝治疗适用于PE的治疗。治疗根据是否存在休克来指导,范围从治疗性抗凝到药物或机械取栓。患者的预后差异很大,取决于患者的心脏和肺部状况以及栓子大小。

相似文献

1
Pathophysiology and Management of Pulmonary Embolism.
Int J Angiol. 2022 Sep 23;31(3):143-149. doi: 10.1055/s-0042-1756204. eCollection 2022 Sep.
2
Acute Pulmonary Embolism: Contemporary Approach to Diagnosis, Risk-Stratification, and Management.
Int J Angiol. 2019 Jun;28(2):100-111. doi: 10.1055/s-0039-1692636. Epub 2019 Jul 5.
5
Clinical prediction of pulmonary embolism in respiratory emergencies.
Thromb Res. 2011 May;127(5):411-7. doi: 10.1016/j.thromres.2011.02.002. Epub 2011 Mar 10.
6
Managing pulmonary embolism from presentation to extended treatment.
Thromb Res. 2014 Feb;133(2):139-48. doi: 10.1016/j.thromres.2013.09.040. Epub 2013 Oct 14.
7
Deep Venous Thrombosis and Pulmonary Embolism.
Curr Treat Options Cardiovasc Med. 2002 Jun;4(3):223-238. doi: 10.1007/s11936-002-0003-7.
8
[Clinical features of 40 elderly patients with pulmonary thromboembolism: a retrospective study].
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Oct;32(10):1236-1240. doi: 10.3760/cma.j.cn121430-20200509-00454.
9
Diagnosis and management of life-threatening pulmonary embolism.
J Intensive Care Med. 2011 Sep-Oct;26(5):275-94. doi: 10.1177/0885066610392658. Epub 2011 May 23.

引用本文的文献

3
Catestatin in Cardiovascular Diseases.
Int J Mol Sci. 2025 Mar 7;26(6):2417. doi: 10.3390/ijms26062417.
5
Venous Thromboembolism: Current Insights and Future Directions.
Int J Angiol. 2024 Jul 8;33(4):250-261. doi: 10.1055/s-0044-1787652. eCollection 2024 Dec.
6
Diagnostic Strategies in Pulmonary Embolism.
Int J Angiol. 2024 Feb 12;33(2):89-94. doi: 10.1055/s-0044-1779661. eCollection 2024 Jun.
7
Epidemiology, Etiology, and Pathophysiology of Pulmonary Embolism.
Int J Angiol. 2024 Apr 12;33(2):76-81. doi: 10.1055/s-0044-1785487. eCollection 2024 Jun.
8
Pulmonary Embolism in Donor Lungs-Incidence and Management.
Int J Angiol. 2024 Mar 15;33(2):128-131. doi: 10.1055/s-0044-1782536. eCollection 2024 Jun.
9
Exploring varied radiologic appearance in pulmonary embolism with CT pulmonary angiography: Case series with literature review.
Radiol Case Rep. 2024 May 23;19(8):3367-3371. doi: 10.1016/j.radcr.2024.04.081. eCollection 2024 Aug.

本文引用的文献

2
Interventional Treatment of Pulmonary Embolism.
Circ Cardiovasc Interv. 2017 Feb;10(2). doi: 10.1161/CIRCINTERVENTIONS.116.004345.
3
Thrombosis: a major contributor to global disease burden.
Semin Thromb Hemost. 2014 Oct;40(7):724-35. doi: 10.1055/s-0034-1390325. Epub 2014 Oct 10.
5
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel.
Thromb Haemost. 2014 May 5;111(5):781-2. doi: 10.1160/TH14-03-0228. Epub 2014 Mar 21.
7
The Anrep effect: 100 years later.
Am J Physiol Heart Circ Physiol. 2013 Jan 15;304(2):H175-82. doi: 10.1152/ajpheart.00508.2012. Epub 2012 Nov 16.
8
Clinical decision rules for excluding pulmonary embolism: a meta-analysis.
Ann Intern Med. 2011 Oct 4;155(7):448-60. doi: 10.7326/0003-4819-155-7-201110040-00007.
9
Bronchoconstriction during alveolar hypocapnia and systemic hypercapnia in dogs with a cardiopulmonary bypass.
Respir Physiol Neurobiol. 2011 Jan 31;175(1):140-5. doi: 10.1016/j.resp.2010.10.004. Epub 2010 Oct 27.
10
Lung surfactant alterations in pulmonary thromboembolism.
Eur J Med Res. 2009 Dec 7;14 Suppl 4(Suppl 4):38-41. doi: 10.1186/2047-783x-14-s4-38.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验